Sugi Predict

Sugi Predict / Compounds / SCHEMBL10179987

SCHEMBL10179987

SCHEMBL10179987

C[C@@H]1CNC[C@H](C(=O)O)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 3/20 0.45
▸ CYP1A2 P05177 2/20 0.45
▸ ALOX15 P16050 2/20 0.45
▸ CYP2C19 P33261 2/20 0.45
▸ SLC1A3 P43003 1/20 0.45
▸ SLC1A2 P43004 1/20 0.45
▸ SLC1A1 P43005 1/20 0.45
▸ TSHR P16473 3/20 0.43
▸ SLC6A1 P30531 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ SLC6A11 P48066 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ SLC6A13 Q9NSD5 1/20 0.43
▸ GABRP O00591 1/20 0.39
▸ GABRD O14764 1/20 0.39
▸ GABRA1 P14867 1/20 0.39
▸ GABRB1 P18505 1/20 0.39
▸ GABRG2 P18507 1/20 0.39
▸ GABRB3 P28472 1/20 0.39
▸ GABRA5 P31644 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25277658 1.00 CYP2D6 (0.45) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL26924945 1.00 CYP2D6 (0.45) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL26925512 1.00 CYP2D6 (0.45) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL16579395 1.00 CYP2D6 (0.45) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL1117719 0.83 CYP2D6 (0.54) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL8256069 0.83 CYP2D6 (0.54) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL9977121 0.82 CHRNB2 (0.36) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
SCHEMBL17743413 0.80 CYP2D6 (0.52) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL20734387 0.80 KDM4E (0.45) CYP2D6SMN1; SMN2CHRNB2CHRNA4CHRNA7
SCHEMBL20734516 0.80 KDM4E (0.45) CYP2D6SMN1; SMN2CHRNB2CHRNA4CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2473499-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-07-11 — — EP claimed
US-12528826-B2 [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2026-01-20 — — US disclosed
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-09-04 — — US disclosed
US-20250270191-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-08-28 — — US disclosed
EP-4536650-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
EP-4536658-A1 1,8-NAPHTHYRIDIN-2-ONE HETEROBIFUNCTIONAL BCL6 DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
EP-4536649-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
WO-2025050016-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-03-06 — — WO disclosed
WO-2025049964-A1 BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-03-06 — — WO disclosed
CN-119317623-A Tricyclic quinolone BCL6 bifunctional degradation agents 树线生物科学公司 2025-01-14 — — CN disclosed
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2024-08-29 — — US disclosed
US-20240217987-A1 INHIBITOR COMPOUNDS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-07-04 — — US disclosed
WO-2023244918-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-21 — — WO disclosed
WO-2023244918-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-21 — — WO disclosed
WO-2023244917-A1 1,8-NAPHTHYRIDIN-2-ONE HETEROBIFUNCTIONAL BCL6 DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-21 — — WO disclosed
WO-2023240038-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-14 — — WO disclosed
WO-2023240038-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-14 — — WO disclosed
EP-2473499-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-07-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528826-B2 [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors BCL6, BCL6B, BCL3 CYP2D6 1628/4885CYP1A2 3827/4885ALOX15 916/4885
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR CYP2D6 363/4885CYP1A2 386/4885ALOX15 1321/4885
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR CYP2D6 363/4885CYP1A2 386/4885ALOX15 1321/4885
US-20250270191-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR CYP2D6 441/4885CYP1A2 262/4885ALOX15 947/4885
US-20240217987-A1 INHIBITOR COMPOUNDS BCL6, BCL6B, BCL3 CYP2D6 2117/4885CYP1A2 4151/4885ALOX15 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.